4
Changes in Ownership
MYRIAD GENETICS INC Filed Acc 0001219036-21-000018
Chief Scientific Officer sold 93,295 shares at an average $33.64 ($3,138,273)
- Chief Scientific Officer acquired 93,295 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
LANCHBURY JERRY S · Chief Scientific Officer
Table I: Non-derivative
8 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2021-07-12 | Exercise or conversion : show line 1 in the form | +36,705 | $26.49 | $972,315 | 269,255 | D |
| 2021-07-12 | Sale : show line 2 in the form | −36,705 | $33.55 | $1,231,431 | 232,550 | D |
| 2021-07-12 | Exercise or conversion : show line 3 in the form | +13,295 | $26.49 | $352,185 | 245,845 | D |
| 2021-07-12 | Sale : show line 4 in the form | −13,295 | $33.55 | $446,075 | 232,550 | D |
| 2021-07-13 | Exercise or conversion : show line 5 in the form | +3,295 | $26.49 | $87,285 | 235,845 | D |
| 2021-07-13 | Sale : show line 6 in the form | −3,295 | $33.69 | $111,012 | 232,550 | D |
| 2021-07-13 | Exercise or conversion : show line 7 in the form | +40,000 | $26.49 | $1,059,600 | 272,550 | D |
| 2021-07-13 | Sale : show line 8 in the form | −40,000 | $33.74 | $1,349,756 | 232,550 | D |
| Open-market sales · 93,295 sh · avg $33.64 · $3,138,273 | ||||||
Table II: Derivative
4 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2021-07-12 | Exercise or conversion : show line 9 in the form Non-Qualified Stock Option (right to buy) | −36,705 | 72,815 | D |
| 2021-07-12 | Exercise or conversion : show line 10 in the form Non-Qualified Stock Option (right to buy) | −13,295 | 59,520 | D |
| 2021-07-13 | Exercise or conversion : show line 11 in the form Non-Qualified Stock Option (right to buy) | −3,295 | 56,225 | D |
| 2021-07-13 | Exercise or conversion : show line 12 in the form Non-Qualified Stock Option (right to buy) | −40,000 | 16,225 | D |
Loading xslF345X03/edgardoc.xml…